ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1UNH | UNITEDHEALTH GROUP INC | Healthcare | $363.01B | 21.93% |
2PFE | PFIZER INC | Healthcare | $164.33B | 9.93% |
3MCK | MCKESSON CORP | Healthcare | $124.35B | 7.51% |
4CVS | CVS HEALTH CORP | Healthcare | $114.88B | 6.94% |
5HCA | HCA HEALTHCARE INC | Healthcare | $104.58B | 6.32% |
6ELV | ELEVANCE HEALTH INC | Healthcare | $92.88B | 5.61% |
7CI | CIGNA GROUP | Healthcare | $78.07B | 4.72% |
8COR | CENCORA INC | Healthcare | $66.67B | 4.03% |
9CAH | CARDINAL HEALTH INC | Healthcare | $64.29B | 3.88% |
10HUM | HUMANA INC | Healthcare | $53.29B | 3.22% |
11TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $50.93B | 3.08% |
12IQV | IQVIA HOLDINGS INC | Healthcare | $44.68B | 2.70% |
13GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $37.00B | 2.24% |
14CNC | CENTENE CORP | Healthcare | $34.79B | 2.10% |
15VTRS | VIATRIS INC | Healthcare | $23.70B | 1.43% |
16THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 1.38% |
17ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $19.79B | 1.20% |
18SOLV | SOLVENTUM CORP | Healthcare | $15.07B | 0.91% |
19BAX | BAXTER INTERNATIONAL INC | Healthcare | $13.32B | 0.80% |
20UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $11.18B | 0.68% |
21MOH | MOLINA HEALTHCARE INC | Healthcare | $10.95B | 0.66% |
22DVA | DAVITA INC | Healthcare | $10.95B | 0.66% |
23OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 0.60% |
24HSIC | HENRY SCHEIN INC | Healthcare | $9.52B | 0.58% |
25PACS | PACS GROUP INC | Healthcare | $7.62B | 0.46% |
26AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $7.56B | 0.46% |
27BLCO | BAUSCH & LOMB CORP | Healthcare | $7.56B | 0.46% |
28PTCT | PTC THERAPEUTICS INC | Healthcare | $5.29B | 0.32% |
29SHC | SOTERA HEALTH CO | Healthcare | $4.66B | 0.28% |
30IONS | IONIS PHARMACEUTICALS INC | Healthcare | $4.55B | 0.27% |
31NVST | ENVISTA HOLDINGS CORP | Healthcare | $3.95B | 0.24% |
32OGN | ORGANON & CO | Healthcare | $3.65B | 0.22% |
33ACHC | ACADIA HEALTHCARE COMPANY INC | Healthcare | $3.52B | 0.21% |
34SGRY | SURGERY PARTNERS INC | Healthcare | $3.48B | 0.21% |
35BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.19% |
36AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.67B | 0.16% |
37ARDT | ARDENT HEALTH INC | Healthcare | $2.49B | 0.15% |
38PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 0.14% |
39PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.15B | 0.13% |
40BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $2.14B | 0.13% |
41FTRE | FORTREA HOLDINGS INC | Healthcare | $1.94B | 0.12% |
42TRLV | TRULIEVE CANNABIS CORP | Healthcare | $1.90B | 0.11% |
43AGL | AGILON HEALTH INC | Healthcare | $1.85B | 0.11% |
44XRAY | DENTSPLY SIRONA INC | Healthcare | $1.83B | 0.11% |
45ASTH | ASTRANA HEALTH INC | Healthcare | $1.77B | 0.11% |
46SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.10% |
47RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $1.66B | 0.10% |
48SNDA | SONIDA SENIOR LIVING INC | Healthcare | $1.63B | 0.10% |
49ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.10% |
50ENOV | ENOVIS CORP | Healthcare | $1.59B | 0.10% |
51TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.10% |
52ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $1.57B | 0.09% |
53CNMD | CONMED CORP | Healthcare | $1.50B | 0.09% |
54NVAX | NOVAVAX INC | Healthcare | $1.45B | 0.09% |
55AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.09% |
56PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.09% |
57LMRI | LUMEXA IMAGING HOLDINGS INC | Healthcare | $1.44B | 0.09% |
58AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.07% |
59TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.22B | 0.07% |
60VOR | VOR BIOPHARMA INC | Healthcare | $1.19B | 0.07% |
61IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.12B | 0.07% |
62ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.10B | 0.07% |
63AHCO | ADAPTHEALTH CORP | Healthcare | $1.07B | 0.06% |
64AORT | ARTIVION INC | Healthcare | $947M | 0.06% |
65SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $859M | 0.05% |
66COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $775M | 0.05% |
67VREX | VAREX IMAGING CORP | Healthcare | $769M | 0.05% |
68GMRS | GMR SOLUTIONS INC | Healthcare | $754M | 0.05% |
69QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.04% |
70KURA | KURA ONCOLOGY INC | Healthcare | $683M | 0.04% |
71DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.04% |
72SRZN | SURROZEN INC | Healthcare | $604M | 0.04% |
73MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.03% |
74RGNX | REGENXBIO INC | Healthcare | $531M | 0.03% |
75PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.03% |
76EOLS | EVOLUS INC | Healthcare | $475M | 0.03% |
77CTEV | CLARITEV CORP | Healthcare | $459M | 0.03% |
78ASPE | ASPEN NEUROSCIENCE INC | Healthcare | $396M | 0.02% |
79EMBC | EMBECTA CORP | Healthcare | $364M | 0.02% |
80EIKN | EIKON THERAPEUTICS INC | Healthcare | $327M | 0.02% |
81ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $326M | 0.02% |
82AGEN | AGENUS INC | Healthcare | $311M | 0.02% |
83EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.02% |
84OFIX | ORTHOFIX MEDICAL INC | Healthcare | $283M | 0.02% |
85LFCR | LIFECORE BIOMEDICAL INC | Healthcare | $243M | 0.01% |
86RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.01% |
87STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.01% |
88INGN | INOGEN INC | Healthcare | $146M | 0.01% |
89BDSX | BIODESIX INC | Healthcare | $109M | 0.01% |
90PARK | PARK DENTAL PARTNERS INC | Healthcare | $101M | 0.01% |
91ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.00% |
92GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.00% |
93XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $1.66T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 45% toward Growth. +5% unclassified (33 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 93 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 93 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 22%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 26.8% | 24.2% |
| 3 yearsp.a. | 17.3% | 1.8% |
| 5 yearsp.a. | 13.3% | 11.4% |
| 10 yearsp.a. | 13.6% | 2.8% |
| Since inceptionp.a. | 12.9% | 3.1% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 26.8% | 19.0% |
| 2025 | 21.0% | 5.2% |
| 2024 | 0.8% | -6.6% |
| 2023 | -1.7% | -19.1% |
| 2022 | 10.2% | 60.4% |
| 2021 | 29.4% | 49.4% |
| 2020 | 10.6% | -29.9% |
| 2019 | 21.7% | -4.3% |
| 2018 | 2.9% | -0.9% |
| 2017 | 19.2% | -17.8% |
| 2016 | -4.6% | 9.1% |
| 2015 | 6.4% | -1.7% |
| 2014 | 25.6% | 4.5% |
| 2013 | 46.2% | 15.8% |
| 2012 | 19.7% | 1.0% |
| 2011 | 16.7% | -2.0% |
| 2010 | 8.7% | -0.1% |
| 2009 | 43.5% | 33.0% |
| 2008 | -42.1% | -30.1% |
| 2007 | 8.0% | 2.4% |
| 2006 | 8.8% | -3.6% |
| 2005 | 31.6% | -0.0% |
| 2004 | 22.8% | 31.5% |
| 2003 | 38.6% | -1.2% |
| 2002 | -16.1% | 15.5% |
| 2001 | 5.7% | 28.9% |
| 2000 | 78.2% | 27.4% |
| 1999 | -14.3% | -34.8% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Leverage Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Leverage signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.